RecruitingNCT05396612
Role of the Immune Environment in Response to Therapy in Breast Cancer
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
300 participants
Start Date
Oct 3, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria1
- Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
Exclusion Criteria1
- Males Children Pregnant individuals
Interventions
OTHERCollection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05396612
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations